GlassScriptPhysician profile
Dawn T Zapinski
NPI 1720086739
$1,496.16
in general payments reported to CMS, 2019-2025
23 companies · $79.63 in 2025
The $79.63 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $145 · 2021: $308 · 2022: $367 · 2024: $22.52 · 2025: $79.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $102.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $274.33 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $258.02 | 2019-2020 | |
| Abbvie INC. | $204.37 | 2021-2025 | |
| Kyowa Kirin, INC. | $117.68 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $97.84 | 2022 | |
| Novo Nordisk INC | $95.43 | 2019-2020 | |
| Horizon Therapeutics Plc | $95.25 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $94.72 | 2021 | |
| Livanova USA, INC. | $44.74 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sanofi Pasteur INC. | $26.76 | 2019 | |
| Lilly USA, LLC | $22.62 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $22.06 | 2019 | |
| Abbott Laboratories | $16.21 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.05 | 2019 | |
| Exact Sciences Corporation | $15.73 | 2025 | The Cologuard Plus Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $15.40 | 2025 | Venaseal |
| Glaxosmithkline, LLC. | $15.18 | 2022 | |
| Pfizer INC. | $15.10 | 2019 | |
| Daiichi Sankyo INC. | $13.84 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.99 | 2020 | |
| Avanir Pharmaceuticals, INC. | $11.55 | 2019 | |
| Biogen, INC. | $11.29 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Zapinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.